The only licensed treatment for the reduction in recurrence of overt hepatic encephalopathy (OHE)1
Evidence supporting XIFAXAN® 550mg treatment
Pivotal Trial Data
Long-term Data
Real world evidence
Guidelines
The impact of hepatic encephalopathy (HE)2
Hepatic encephalopathy is a major complication of cirrhosis.2
Approximately 50% of people with cirrhosis will develop clinically apparent hepatic encephalopathy at some stage after diagnosis - the risk being around 5-25% within 5 years.2
Hospital admissions are common and inpatient stays often prolonged. The presence of hepatic encephalopathy is associated with a significant increase in mortality; survival after the first episode is 42% at 1 year and 23% at 3 years.2